Hypophosphatemic rickets: Unraveling the role of FGF23

Calcified Tissue International

Volumn 91, Issue 5, 2012, Pages 297-306

  Pettifor, John M ^a   Thandrayen, Kebashni ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

ADHR; ARHR; DMP1; FGF23; Hypophosphatemic rickets; PHEX; XLH

Indexed keywords

CALCITONIN; CALCITRIOL; DENTIN MATRIX PROTEIN 1; FERRITIN; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 23 ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IRON; KLOTHO PROTEIN; MONOCLONAL ANTIBODY; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; DRUG EFFECT; DRUG RESPONSE; FGF23 GENE; GENE; GENE MUTATION; HORMONAL REGULATION; HUMAN; HYPOPHOSPHATEMIC RICKETS; NONHUMAN; ONCOGENIC OSTEOMALACIA; OSTEOMALACIA; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RICKETS; THERAPY RESISTANCE; X LINKED HYPOPHOSPHATEMIC RICKETS;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT;

EID: 84867580772     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9651-0     Document Type: Review

References (67)

1. Econs MJ, Drezner MK (1994) Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med 330:1679-1681
2. Kumar R (1997) Phosphatonin - a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol Dial Transplant 12:11-13
3. White KE, Evans WE, O'Riordan JL, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM (2000) Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
4. Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumorinduced osteomalacia. Endocr Relat Cancer 18:R53-R77
5. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron RP (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692
6. Sapir-Koren R, Livshits G (2011) Bone mineralization and regulation of phosphate homeostasis. IBMS BoneKEy 8:286-300
7. Zhang R, Lu Y, Ye L, Yuan B, Yu S, Qin C, Xie Y, Gao T, Drezner MK, Bonewald LF, Feng JQ (2011) Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res 26:1047-1056
8. Perwad F, Portale AA (2011) Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol 347:17-24
9. Martin A, David V, Quarles LD (2012) Regulation and function of the FGF23/Klotho endocrine pathways. Physiol Rev 92:131- 155
10. Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M (2011) Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 301:F371-F377
11. Quarles LD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8:276-286
12. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086
13. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182
14. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS, Mohammadi M (2007) Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27:3417-3428
15. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuro-o M, Mohammadi M (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 107:407-412
16. Saito H, Maeda A, Ohtomo Si, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto Ki, Fukushima N (2005) Circulating FGF-23 is regulated by 1a,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543-2549
17. Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor- 23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519-1524
18. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419-422
19. Isakova T (2012) Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 21:334-340
20. Wahl P, Wolf M (2012) FGF23 in chronic kidney disease. Adv Exp Med Biol 728:107-125
21. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez- Moreno JM, Ramirez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, Rodriguez M, Felsenfeld A, Almaden Y (2012) Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23:1190-1197
22. David V, Quarles LD (2010) ASARM mineralization hypothesis: a bridge too far? J Bone Miner Res 25:692-694
23. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315
24. Lu Y, Yuan B, Qin C, Cao Z, Xie Y, Dallas SL, McKee MD, Drezner MK, Bonewald LF, Feng JQ (2011) The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment. J Bone Miner Res 26:331-340
25. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273-278
26. HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130-136
27. David V, Martin A, Hedge AM, Drezner MK, Rowe PSN (2011) ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol 300:F783-F791
28. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D (2009) Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150:4835-4845
29. Durham BH, Joseph F, Bailey LM, Fraser WD (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 44:463-466
30. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541-3549
31. Prentice A, Ceesay M, Nigdikar S, Allen SJ, Pettifor JM (2008) FGF23 is elevated in Gambian children with rickets. Bone 42: 788-797
32. Braithwaite V, Jarjou LMA, Goldberg GR, Prentice A (2012) Iron status and fibroblast growth factor-23 in Gambian children. Bone 50:1351-1356
33. Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392-401
34. Sabbagh Y, Carpenter TO, Demay MB (2005) Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA 102:9637-9642
35. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T (2009) Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24:1879-1888
36. Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD (2007) Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293:E1636-E1644
37. Glorieux FH, Marie PJ, Pettifor JM, Delvin EE (1980) Bone response to phosphate salts, ergocalciferol and calcitriol in hypophosphatemic vitamin-D resistant rickets. N Engl J Med 303: 1023-1031
38. Marie PJ, Travers R, Glorieux FH (1981) Healing of rickets with phosphate supplementation in the hypophosphatemic male mouse. J Clin Invest 67:911-914
39. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42: 1235-1239
40. Igaki JM, Yamada M, Yamazaki Y, Koto S, Izawa M, Ariyasu D, Suzuki E, Hasegawa H, Hasegawa Y (2011) High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH. Endocr J 58:647-655
41. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663
42. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055-2061
43. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM (2010) Circulating levels of soluble Klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95:E352-E357
44. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ (2010) Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95:1846-1850
45. Fukumoto S, Shimizu Y (2011) Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 29: 507-514
46. Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3357-3365
47. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108:E1146-E1155
48. Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler Peck CM, Wodajo FM, Chang R, Collins MT (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26:1295-1302
49. Hu FK, Yuan F, Jiang CY, Lv DW, Mao BB, Zhang Q, Yuan ZQ, Wang Y (2011) Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature. Chin J Cancer 30:794-804
50. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381-1388
51. Goodman JR, Gelbier MJ, Bennett JH, Winter GB (1998) Dental problems associated with hypophosphatemic vitamin D resistant rickets. Int J Paediatr Dent 8:19-28
52. Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM (2009) Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int 85: 235-246
53. Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M (2007) Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis 13:482-489
54. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843-1848
55. Savio RM, Gosnell JE, Posen S, Reeve TS, Delbridge LW (2004) Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg 139:218-222
56. Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, Vestergaard P, Ralston SH, Albagha OM, Poulsen S, Haubek D, Gjorup H, Hintze H, Andersen MG, Heickendorff L, Hjelmborg J, Gram J (2010) Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 87:108-119
57. Oliveri MB, Cassinelli H, Bergada C, Mautalen CA (1991) Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets (XLH). Bone Miner 12: 91-100
58. Reid IR, Murphy WA, Hardy DC, Teitelbaum SL, Bergfeld MA, Whyte MP (1991) X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med 90:63-69
59. Fukumoto S (2012) What's new in FGF23 research? BoneKEy Rep. doi:10.1038/bonekey.2012.111
60. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509-1518
61. Liu ES, Carpenter TO, Gundberg CM, Simpson CA, Insogna KL (2011) Calcitonin administration in X-linked hypophosphatemia. N Engl J Med 364:1678-1680
62. Carpenter T (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1-9
63. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267-272
64. Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey JG (2000) Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune- Albright fibrous dysplasia of bone. J Bone Miner Res 15:120-128
65. Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, Nabeshima Yi, Reyes-Mugica M, Carpenter TO, Lifton RP (2008) A translocation causing increased a-Klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455-3460
66. Lorenz-Depiereux B, et-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D, Hochberg Z, Strom TM (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193-201
67. Bastepe M, Juppner H (2008) Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 9:171-180